158 related articles for article (PubMed ID: 27465066)
1. Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model.
An Y; Liu T; He J; Wu H; Chen R; Liu Y; Wu Y; Bai Y; Guo X; Zheng Q; Liu C; Yin J; Li D; Ren G
J Biomed Sci; 2016 Jul; 23(1):55. PubMed ID: 27465066
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Newcastle Disease virus Expressing IL15 Demonstrates Promising Antitumor Efficiency in Melanoma Model.
Niu Z; Bai F; Sun T; Tian H; Yu D; Yin J; Li S; Li T; Cao H; Yu Q; Wu Y; Ren G; Li D
Technol Cancer Res Treat; 2015 Oct; 14(5):607-15. PubMed ID: 24645750
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic Newcastle disease virus expressing chimeric antibody enhanced anti-tumor efficacy in orthotopic hepatoma-bearing mice.
Wei D; Li Q; Wang XL; Wang Y; Xu J; Feng F; Nan G; Wang B; Li C; Guo T; Chen ZN; Bian H
J Exp Clin Cancer Res; 2015 Dec; 34():153. PubMed ID: 26689432
[TBL] [Abstract][Full Text] [Related]
4. Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy.
He J; Pan Z; Tian G; Liu X; Liu Y; Guo X; An Y; Song L; Wu H; Cao H; Yu D; Che R; Xu P; Rasoul LM; Li D; Yin J
Virus Res; 2016 Aug; 221():23-9. PubMed ID: 27164362
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Newcastle disease virus Anhinga strain (NDV/Anh-EGFP) for hepatoma therapy.
Wu Y; Yan S; Lv Z; Chen L; Geng J; He J; Yu Q; Yin J; Ren G; Li D
Technol Cancer Res Treat; 2014 Apr; 13(2):169-75. PubMed ID: 23819497
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Newcastle disease virus expressing human TRAIL as a potential candidate for hepatoma therapy.
Wu Y; He J; Geng J; An Y; Ye X; Yan S; Yu Q; Yin J; Zhang Z; Li D
Eur J Pharmacol; 2017 May; 802():85-92. PubMed ID: 28246027
[TBL] [Abstract][Full Text] [Related]
7. Newcastle disease virus expressing an angiogenic inhibitor exerts an enhanced therapeutic efficacy in colon cancer model.
Meng F; Cao Y; Su H; Liu T; Tian L; Zhang Y; Yang J; Xiao W; Li D
PLoS One; 2022; 17(4):e0264896. PubMed ID: 35381011
[TBL] [Abstract][Full Text] [Related]
8. Identification of Optimal Insertion Site in Recombinant Newcastle Disease Virus (rNDV) Vector Expressing Foreign Gene to Enhance Its Anti-Tumor Effect.
Pan Z; He J; Rasoul LM; Liu Y; Che R; Ding Y; Guo X; Yang J; Zou D; Zhang H; Li D; Cao H
PLoS One; 2016; 11(10):e0164723. PubMed ID: 27736965
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Newcastle Disease Virus Encoding IL-12 and/or IL-2 as Potential Candidate for Hepatoma Carcinoma Therapy.
Ren G; Tian G; Liu Y; He J; Gao X; Yu Y; Liu X; Zhang X; Sun T; Liu S; Yin J; Li D
Technol Cancer Res Treat; 2016 Oct; 15(5):NP83-94. PubMed ID: 26303327
[TBL] [Abstract][Full Text] [Related]
10. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy.
Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS
Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746
[TBL] [Abstract][Full Text] [Related]
11. Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy.
Wu Y; He J; An Y; Wang X; Liu Y; Yan S; Ye X; Qi J; Zhu S; Yu Q; Yin J; Li D; Wang W
J Pharmacol Sci; 2016 Sep; 132(1):24-30. PubMed ID: 27174862
[TBL] [Abstract][Full Text] [Related]
12. TNF-related Apoptosis-inducing Ligand Delivered by rNDV is a Novel Agent for Cancer Gene Therapy.
Bai FL; Tian H; Yu YH; Yin JC; Ren GP; Zhou B; Li DS
Technol Cancer Res Treat; 2015 Dec; 14(6):737-46. PubMed ID: 24988059
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Newcastle disease virus expressing the co-stimulator OX40L as immunopotentiator for colorectal cancer therapy.
Tian L; Liu T; Jiang S; Cao Y; Kang K; Su H; Ren G; Wang Z; Xiao W; Li D
Gene Ther; 2023 Feb; 30(1-2):64-74. PubMed ID: 34602608
[TBL] [Abstract][Full Text] [Related]
14. A p53-independent apoptotic mechanism of adenoviral mutant E1A was involved in its selective antitumor activity for human cancer.
Fang L; Cheng Q; Zhao J; Ge Y; Zhu Q; Zhao M; Zhang J; Zhang Q; Li L; Liu J; Zheng J
Oncotarget; 2016 Jul; 7(30):48309-48320. PubMed ID: 27340782
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma.
Buijs P; van Nieuwkoop S; Vaes V; Fouchier R; van Eijck C; van den Hoogen B
Viruses; 2015 Jun; 7(6):2980-98. PubMed ID: 26110582
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway.
Fan X; Lu H; Cui Y; Hou X; Huang C; Liu G
Exp Ther Med; 2018 May; 15(5):4522-4530. PubMed ID: 29731836
[TBL] [Abstract][Full Text] [Related]
17. [Rescue of a recombinant Newcastle disease virus expressing the green fluorescent protein].
Ge JY; Wen ZY; Wang Y; Bao ED; Bu ZG
Wei Sheng Wu Xue Bao; 2006 Aug; 46(4):547-51. PubMed ID: 17037052
[TBL] [Abstract][Full Text] [Related]
18. Cell-specific expression of artificial microRNAs targeting essential genes exhibit potent antitumor effect on hepatocellular carcinoma cells.
Mao C; Liu H; Chen P; Ye J; Teng L; Jia Z; Cao J
Oncotarget; 2015 Mar; 6(8):5707-19. PubMed ID: 25691059
[TBL] [Abstract][Full Text] [Related]
19. A recombinant Newcastle disease virus (NDV) expressing infectious laryngotracheitis virus (ILTV) surface glycoprotein D protects against highly virulent ILTV and NDV challenges in chickens.
Kanabagatte Basavarajappa M; Kumar S; Khattar SK; Gebreluul GT; Paldurai A; Samal SK
Vaccine; 2014 Jun; 32(28):3555-63. PubMed ID: 24793943
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor efficacy of the recombinant Newcastle disease virus rNDV-IL15 on melanoma models].
Niu ZS; Bai FL; Sun T; Tian H; Yin JC; Cao HW; Yu D; Tian GY; Wu YZ; Li DS; Ren GP
Yao Xue Xue Bao; 2014 Mar; 49(3):310-5. PubMed ID: 24961100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
